Aims: The study aimed to evaluate the effects of tolvaptan treatment on survival of patients with decompensated liver cirrhosis with refractory ascites.
Methods: This multicenter, retrospective, observational study included patients with cirrhosis who were treated with tolvaptan for hepatic ascites refractory to conventional diuretics. Patients who could and could not decrease accompanying diuretics within 1 month after tolvaptan administration were defined as the "Decreased" and "Not-decreased" groups, respectively.
Results: Median body weight change 1 week after tolvaptan treatment was -1.95 kg, with the 50% of patients experiencing a 2 kg/week reduction. Spot urinary sodium was found to be a better predictor of tolvaptan response than liver function and liver fibrosis markers. Median survival was significantly longer (not reached versus 116 days, p = 0.005) and serum creatinine concentrations 12 weeks after tolvaptan administration significantly lower (0.99 vs. 1.55 mg/dL, p < 0.05) in the Decreased than in the Not-decreased group. Multivariate analysis showed that the presence of viable hepatocellular carcinoma (hazards ratio [HR] 2.14, p = 0.02) and a decrease in diuretics were independently prognostic of survival (HR 0.36, p < 0.01).
Conclusions: The maintenance of renal function is essential in enhancing survival of patients with cirrhosis. Doses of diuretics should be adjusted appropriately during tolvaptan treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000489258 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial.
Clin Exp Nephrol
January 2025
Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ, USA.
Background: Despite of long-lasting tolvaptan treatment, individual renal outcomes are unclear in autosomal dominant polycystic kidney disease (ADPKD). This post-hoc analysis of the TEMPO 3:4 trial aimed to evaluate the predictability of estimated height-adjusted total kidney volume growth rate (eHTKV-α) on renal outcomes.
Methods: In TEMPO 3:4, 1445 patients with ADPKD were randomised to tolvaptan or placebo for 3 years.
Arginine vasopressin and angiotensin II coregulate Aquaporin 2 expression in M-1 cells.
Biochem Biophys Res Commun
December 2024
School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China; Anhui Provincial Key Laboratory of Chinese Medicinal Formula, Hefei, China; Institute for Pharmacodynamics and Safety Evaluation of Chinese Medicine, Anhui Academy of Chinese Medicine, Hefei, China. Electronic address:
Objective: The aim of this study was to explore the impact of arginine vasopressin (AVP) and angiotensin II (Ang II) on aquaporin 2 (AQP2) expression in M - 1 cells.
Methods: M - 1 cells were stimulated with desmopressin (dDAVP) and Ang II, followed by treatment with tolvaptan and losartan. The expression and protein levels of V2R, AT1R, AQP2, and p-S256AQP2 were measured via ELISA, western blotting, RT-qPCR, and immunofluorescence.
Efficacy and safety of low-dose tolvaptan (7.5mg) in the treatment of inpatient hyponatraemia: a retrospective study.
Endocr Pract
December 2024
Department of Endocrinology, King's College Hospital NHS Foundation Trust, London, United Kingdom. Electronic address:
Objectives: The recommended dose of tolvaptan for hyponatraemia secondary to SIADH is 15mg. We evaluated the efficacy of an initial 7.5mg dose and determined the frequency where sodium (Na+) correction exceeded safe limits, defined as an increment of ≥10 mmol/L, within the initial 8 or 24 hours of administration.
View Article and Find Full Text PDFEmpagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial.
BMJ Open
December 2024
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary condition that causes the formation of cysts primarily in the kidneys. The continuous growth of multiple cysts leads to the destruction of functional parenchyma, which may progress to end-stage kidney disease. Tolvaptan is the only drug specifically approved for slowing down the progression of ADPKD.
View Article and Find Full Text PDFComparative study of the effectiveness of tolvaptan versus urea in patients with hyponatremia caused by SIADH.
Rev Clin Esp (Barc)
December 2024
Unidad de Medicina Oral, Cirugía Oral e Implantología, Facultad de Medicina y Odontología, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
Background And Objectives: Hyponatraemia is common in elderly and hospitalised patients, often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). This study evaluates the efficacy and safety of tolvaptan and urea in patients with hyponatraemia and SIADH.
Materials And Methods: An observational cohort study was conducted on 198 patients with SIADH and hyponatraemia (Na+ <135 mmol/L) at the Complejo Hospitalario Universitario de Pontevedra from January 2015 to May 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!